International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1610-1616 www.ijprajournal.com ISSN: 2456-4494

Tissue inhibitor of metalloproteinase-1 (TIMP-1) – Elevated in liver fibrosis

Km Parul Singh[1*], Meera kumari[2].
1. Student, Goel Institute of Pharmacy and Sciences, Lucknow - 226010 UP India.
2. Assistant Professor, Goel Institute of Pharmacy and Sciences, Lucknow - 226010 UP India.
Corresponding author:*Km Parul Singh*

Date of Submission: 10-06-2025 Date of Acceptance: 20-06-2025

ABSTRACT
Liver diseases, ranging from mild hepatitis to cirrhosis and hepatocellular carcinoma, represent a significant global health burden. Early diagnosis and accurate staging are critical for effective management. Biomarkers have emerged as essential tools in evaluating liver function, injury, inflammation, fibrosis, and regeneration. Among these, Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) has gained considerable attention for its role in liver fibrogenesis. TIMP-1 inhibits matrix metalloproteinases, thereby contributing to extracellular matrix accumulation and fibrosis progression. This review categorizes liver biomarkers into functional, inflammatory, fibrotic, and genomic classes, with a particular focus on TIMP-1 and its diagnostic, prognostic, and therapeutic relevance. Additionally, we explore non-invasive biomarker panels such as the ELF panel, which incorporates TIMP-1, to assess liver fibrosis severity without the need for biopsy. Despite their utility, biomarker application faces challenges including variability, sensitivity, and standardization. Emerging tools like omics technologies and AI-driven diagnostics offer promising avenues to overcome these limitations and enhance biomarker-based liver disease management.

Keywords: Liver fibrosis, TIMP-1, liver biomarkers, extracellular matrix, ELF panel, non-invasive diagnosis, hepatic stellate cells, liver disease, metalloproteinase inhibition, fibrosis staging

I. INTRODUCTION

1. Overview of Liver Structure and Function

The liver is the largest internal organ in the human body, weighing approximately 1.5 kg in adults. It is a vital metabolic hub located in the upper right quadrant of the abdomen, playing essential roles in digestion, metabolism, detoxification, and storage. Structurally, the liver is composed of lobules, the functional units, made up of hepatocytes arranged around a central vein. These hepatocytes perform a wide range of biochemical functions, including the synthesis of plasma proteins (e.g., albumin, clotting factors), bile production, and conversion of nutrients. The liver also contains non-parenchymal cells such as Kupffer cells, hepatic stellate cells, and sinusoidal endothelial cells, each playing specific roles in immune regulation, vitamin A storage, and filtration of blood. The dual blood supply from the hepatic artery and portal vein supports its complex metabolic and detoxification functions. Given its multifunctionality and exposure to toxins, the liver is susceptible to a variety of insults leading to acute or chronic diseases, including hepatitis, cirrhosis, and hepatocellular carcinoma.



Significance of Biomarkers in Liver Disease Diagnosis and Prognosis

Biomarkers serve as measurable indicators of physiological or pathological processes and are critical tools in modern clinical hepatology. In liver disease, biomarkers aid in early detection, differential diagnosis, staging, monitoring

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1610-1616 www.ijprajournal.com ISSN: 2456-4494

therapeutic response, and predicting prognosis. Conventional serum biomarkers like alanine aminotransferase (ALT), aspartate aminotransferase (AST), bilirubin, and alkaline phosphatase (ALP) are commonly used but lack specificity for particular disease etiologies. Therefore, emerging biomarkers such as microRNAs (e.g., miR-122), keratin-18 fragments, and tissue inhibitor of metalloproteinase-1 (TIMP-1) are gaining attention due to their potential to detect fibrosis, inflammation, or hepatocellular injury with greater accuracy. Additionally, non-invasive fibrosis scores and imaging-based biomarkers (e.g., FibroScan®) are increasingly replacing liver biopsies. The integration of novel biomarker panels with traditional tests enhances diagnostic precision, facilitates early intervention, and improves patient outcomes.

Scope and Objectives of the Review

This review aims to provide a comprehensive analysis of the current landscape of liver-specific biomarkers, highlighting their clinical utility across various liver pathologies such as viral hepatitis, non-alcoholic fatty liver disease (NAFLD), alcoholic liver disease (ALD), and hepatocellular carcinoma (HCC). The objectives include (i) summarizing established and emerging biomarkers with diagnostic and prognostic significance; (ii) evaluating their sensitivity, specificity, and limitations; and (iii) discussing recent advancements in biomarker discovery through omics technologies and translational research. Furthermore, the review explores the role of biomarker-guided management in personalized medicine approaches for liver disease patients. Through this evaluation, we aim to identify gaps in current clinical practice and future directions for biomarker research in hepatology.

2. Classification of Liver Biomarkers

Liver biomarkers are critical tools used in clinical and research settings to assess liver function, detect injury, monitor disease progression, and evaluate treatment response. They can be broadly classified based on the physiological processes they represent.

Table 1: Classification of Liver Biomarkers Based on Function

Category	Biomarker Examples	Function	Clinical Relevance
Liver function	ALT, AST, ALP, GGT, Bilirubin	Enzyme activity & metabolic byproducts	Liver injury, bile obstruction
Inflammation	CRP, IL-6, TNF-α	Acute phase reactants	Inflammatory liver diseases
Fibrosis	TIMP-1, PIIINP, Hyaluronic acid, α-SMA	ECM remodeling, fibrosis staging	Chronic hepatitis, NAFLD, cirrhosis
Oxidative stress	MDA, SOD, GSH	Redox imbalance	Alcoholic liver disease, NASH
Regeneration	HGF, Ki-67, CK-18	Cell proliferation/apoptosis	Liver repair, cancer
Genomic/Molecular	miRNA-122, miRNA-21, lncRNAs	Gene regulation	Emerging diagnostics, HCC

Biochemical biomarkers include enzymes that are released into the bloodstream following hepatocellular injury. Among them, alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are the most commonly used indicators of hepatocellular damage. ALT is more specific to liver injury, while AST is also present in cardiac and skeletal muscle. Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) serve as cholestatic markers, indicating bile duct obstruction or damage. Elevated levels of these enzymes are commonly seen in hepatitis, cirrhosis, and drug-induced liver injury (Giannini et al., 2005).

Inflammatory and immune markers such as C-reactive protein (CRP), interleukins (e.g., IL-6), and tumor necrosis factor-alpha (TNF-α) are elevated in liver inflammation and immune-mediated liver diseases. These markers are crucial for evaluating liver conditions associated with systemic inflammation such as autoimmune hepatitis and non-alcoholic steatohepatitis (NASH). Additionally, immune cell-derived cytokines can indicate ongoing immunological activity within the hepatic tissue (Tilg &Moschen, 2010).

Fibrosis-specific markers help in detecting the extent of liver scarring. Examples include hyaluronic acid, tissue inhibitor of

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1610-1616 www.ijprajournal.com ISSN: 2456-4494

metalloproteinases-1 (TIMP-1), and procollagen III N-terminal peptide (PIIINP). These markers reflect extracellular matrix remodeling and have been validated as non-invasive alternatives to liver biopsy in fibrosis staging, particularly in hepatitis C and non-alcoholic fatty liver disease (NAFLD) (Wang et al., 2018). The FibroTest and ELF (Enhanced Liver Fibrosis) score combine multiple such markers to increase diagnostic accuracy.

Oxidative stress markers provide insight into cellular damage caused by reactive oxygen species (ROS). Biomarkers like malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and reduced glutathione (GSH) indicate oxidative stress in liver diseases including alcoholic liver disease, viral hepatitis, and drug-induced hepatotoxicity. These markers are important in understanding the pathophysiology of liver injury and in assessing the efficacy of antioxidant therapies (Poli, 2000).

Regeneration and proliferation markers reflect the liver's ability to repair itself. Alpha-fetoprotein (AFP) is widely used to assess liver regeneration and is also a diagnostic marker for hepatocellular carcinoma (HCC). Other markers include hepatocyte growth factor (HGF) and Ki-67, a nuclear protein associated with cell proliferation. These biomarkers are vital in assessing regenerative responses following hepatic injury or partial hepatectomy (Marrero et al., 2009).

Molecular and genomic biomarkers involve changes at the DNA, RNA, and protein expression levels. These include mutations in genes such as TP53, epigenetic modifications, and microRNA profiles that are associated with disease-specific patterns in HCC, viral hepatitis, and drug-induced liver injury. The use of omics-based technologies—genomics, transcriptomics, proteomics—has expanded the potential of molecular biomarkers in personalizing liver disease diagnostics and therapeutics (Kew, 2013).

3. Liver Fibrosis and Its Pathophysiology

Liver fibrosis is a dynamic pathological process characterized by excessive deposition of extracellular matrix (ECM) components, particularly collagen, due to chronic liver injury caused by hepatitis viruses, alcohol abuse, non-alcoholic steatohepatitis (NASH), or autoimmune diseases. Mechanisms of liver fibrosis development include repeated hepatocellular injury and inflammation, which activate fibrogenic pathways leading to ECM accumulation. The wound-healing response becomes maladaptive in chronic injury, resulting in fibrotic scarring and architectural distortion of the liver parenchyma. A central component in fibrosis is the activation of hepatic stellate cells (HSCs). In the healthy liver, HSCs remain quiescent, storing vitamin A, but upon injury, they transdifferentiate into myofibroblast-like cells that secrete type I and III collagen, fibronectin, and matrix metalloproteinases (MMPs), contributing to fibrotic tissue formation.

Table 2: Role of TIMP-1 in Liver Fibrosis

Feature	Description
Full Name	Tissue Inhibitor of Metalloproteinase-1
Function	Inhibits MMPs; promotes ECM accumulation
Source	Activated hepatic stellate cells
Clinical Elevation	Seen in chronic hepatitis, NAFLD, cirrhosis
Diagnostic Use	Included in ELF panel; correlates with fibrosis
Limitations	May be influenced by systemic inflammation

Cytokines and growth factors involved in liver fibrosis include transforming growth factor-beta (TGF-β), platelet-derived growth factor (PDGF), tumor necrosis factor-alpha (TNF-α), and interleukins such as IL-1β and IL-6. TGF-β is considered the master regulator of fibrosis, inducing HSC activation and collagen synthesis. PDGF is a potent mitogen that promotes HSC proliferation and migration. These cytokines mediate complex autocrine and paracrine signaling that sustains fibrogenesis. In addition, 2.4 oxidative stress markers play a significant role; reactive oxygen species (ROS) generated by damaged hepatocytes and infiltrating inflammatory cells lead to lipid peroxidation, DNA damage, and further HSC activation. Markers such as malondialdehyde (MDA), 4-hydroxynonenal (4-HNE), and increased NADPH oxidase activity are indicative of oxidative stress during fibrosis progression.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1610-1616 www.ijprajournal.com ISSN: 2456-4494

Table 3: Comparison of Key Fibrosis Biomarkers

Biomarker	Source	Specificity to Liver	Use in Panels	Diagnostic Value
TIMP-1	ECM inhibitor	High	ELF	Moderate to high
Hyaluronic acid	ECM component	Moderate	ELF, FibroTest	Moderate
PIIINP	Collagen synthesis	Moderate	ELF	Moderate
α-SMA	Stellate cell activation	High	Histological	High (in tissue)
TGF-β	Cytokine	Low (not liver-specific)	Research use	Context-dependent

Liver tissue also attempts to counterbalance injury through 2.5 regeneration and proliferation markers, such as proliferating cell nuclear antigen (PCNA), Ki-67, and hepatocyte growth factor (HGF). These markers reflect hepatocyte proliferation during regenerative responses, although persistent injury impairs full tissue restoration. Lastly, 2.6 molecular and genomic biomarkers have emerged as promising tools for assessing liver fibrosis. These include serum markers like hyaluronic acid, TIMP-1 (tissue inhibitor of metalloproteinases-1), and procollagen III N-terminal peptide (PIIINP), as well as gene expression profiles related to fibrogenic pathways. Recent advances in transcriptomics, microRNAs (e.g., miR-122, miR-21), and methylation patterns have provided insights into the molecular mechanisms underlying fibrosis and hold potential for early diagnosis and personalized therapy.

4. TIMP-1: A Key Biomarker in Liver Fibrosis

Tissue Inhibitor of Metalloproteinases-1 (TIMP-1) is a glycoprotein that plays a central role in the regulation of extracellular matrix (ECM) remodeling by inhibiting matrix metalloproteinases (MMPs), particularly MMP-9. Structurally, TIMP-1 is composed of 184 amino acids with distinct N- and C-terminal domains, where the N-terminal domain is primarily responsible for MMP inhibition (Nagase et al., 2006). In the context of liver fibrosis, TIMP-1 expression is markedly elevated due to activation of hepatic stellate cells (HSCs), which are central players in fibrogenesis. TIMP-1 impedes ECM degradation by neutralizing MMP activity, leading to excessive collagen accumulation and scar tissue formation in the liver parenchyma (Iredale, 2007). Mechanistically, TIMP-1 also exerts anti-apoptotic effects on HSCs, promoting their survival and thus prolonging fibrotic activity (Murphy, 2011). Clinically, elevated serum levels of TIMP-1 correlate strongly with fibrosis severity in various chronic liver diseases, including hepatitis C, non-alcoholic steatohepatitis (NASH), and alcoholic liver disease (Schuppan & Afdhal, 2008). In comparison with other fibrosis markers like hyaluronic acid, procollagen III N-terminal peptide (PIIINP), and α-smooth muscle actin (α-SMA), TIMP-1 demonstrates higher stability in serum and less variability, making it a reliable indicator in non-invasive fibrosis scoring systems such as the ELF (Enhanced Liver Fibrosis) test (Wells et al., 2003). Moreover, its diagnostic accuracy is enhanced when used in combination with other markers, contributing to improved sensitivity and specificity for staging liver fibrosis. Importantly, TIMP-1 also has prognostic value; persistently high levels have been associated with poor clinical outcomes and increased risk of liver-related complications, including cirrhosis and hepatocellular carcinoma (HCC) (Naveau et al., 2009). Therefore, TIMP-1 serves not only as a mechanistic driver of fibrosis but also as a clinically valuable biomarker for the diagnosis, staging, and prognosis of chronic liver diseases.

Table 4: Non-Invasive Diagnostic Panels Including TIMP-1

Panel Name	Included Biomarkers	Clinical Use	Strengths	Limitations
ELF Panel	TIMP-1, PIIINP, HA	Fibrosis staging	Non-invasive, validated	Cost, limited in early-stage disease
FibroTest	α2-macroglobulin, haptoglobin, GGT, etc.	Fibrosis assessment	Broad utility	Needs standardization
FIB-4 Index	Age, AST, ALT, platelets	Cirrhosis screening	Simple, cost-effective	Less accurate in intermediate stages

5. Clinical Applications of TIMP-1 and Related Markers

Tissue inhibitor of metalloproteinases-1 (TIMP-1) has emerged as a promising biomarker in various chronic liver diseases due to its role in regulating matrix metalloproteinases (MMPs) and modulating extracellular matrix remodeling. In chronic hepatitis B and C, elevated TIMP-1 levels

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1610-1616 www.ijprajournal.com ISSN: 2456-4494

correlate significantly with hepatic inflammation and fibrotic progression, suggesting its potential use in monitoring disease severity and treatment response (Paradis et al., 2001). Similarly, in non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), TIMP-1 is upregulated in parallel with histological fibrosis stages, reinforcing its use in non-invasive diagnostic panels such as the ELF (Enhanced Liver Fibrosis) score (Roh et al., 2022). In alcoholic liver disease (ALD), chronic alcohol exposure leads to hepatic stellate cell activation and increased TIMP-1 expression, promoting fibrogenesis and impeding matrix degradation. Elevated serum TIMP-1 levels in ALD patients have been linked with advanced fibrosis and poor prognosis (Moreno et al., 2005). In cases of cirrhosis and hepatocellular carcinoma (HCC), TIMP-1 not only marks fibrotic progression but also shows potential oncogenic activity. Studies suggest that TIMP-1 can support tumorigenesis through anti-apoptotic signaling and angiogenesis promotion (Yu et al., 2010). Therefore, TIMP-1 serves as a multifaceted biomarker useful in diagnosing, staging, and prognosticating liver diseases, either independently or in combination with other markers like hyaluronic acid and PIIINP.

Table 5: Clinical Applications of TIMP-1 in Various Liver Diseases

Liver Condition	TIMP-1 Level	Diagnostic Utility	Remarks
Chronic hepatitis B/C	Elevated	Moderate	Reflects fibrosis progression
NAFLD / NASH	Elevated	High in NASH	Linked with steatosis + fibrosis
Alcoholic liver disease	Elevated	Moderate	Co-elevation with GGT common
Cirrhosis	Significantly elevated	High	Correlates with decompensation risk
Hepatocellular carcinoma	Variable	Under research	Potential as prognostic marker

6. Limitations and Challenges in Biomarker Use

Despite the promising role of biomarkers in the diagnosis and monitoring of liver diseases, several limitations hinder their clinical utility. One major concern is **sensitivity and specificity**, as many biomarkers may not accurately distinguish between early and advanced stages of liver pathology or between different liver conditions. For instance, alpha-fetoprotein (AFP), a commonly used marker for hepatocellular carcinoma (HCC), has limited sensitivity, especially in early-stage tumors (Zhang et al., 2014). Additionally, **variability due to age, gender, or comorbidities** poses challenges in interpreting biomarker levels. For example, levels of serum biomarkers such as hyaluronic acid and TIMP-1 can be influenced by systemic inflammation, metabolic disorders, or renal function (Sterling et al., 2006). Another significant hurdle lies in the **lack of standardization in assays**, which affects reproducibility across laboratories. Different assay techniques or sample handling protocols can lead to inconsistent results, limiting cross-study comparisons. Moreover, there is a critical **need for validation in large and diverse populations** before biomarkers can be routinely used in clinical practice. Many studies reporting promising results are based on small cohorts, which may not reflect real-world scenarios (Wong et al., 2018). Therefore, robust, multicentric studies are essential to confirm diagnostic accuracy and clinical relevance.

Cirrhosis and Hepatocellular Carcinoma (HCC) (6.4)

Cirrhosis, the end-stage of chronic liver disease, significantly increases the risk of developing hepatocellular carcinoma (HCC). Biomarkers play a crucial role in the surveillance and early detection of HCC in cirrhotic patients. However, their efficacy is often compromised due to overlapping biomarker expression in cirrhosis and malignancy. For instance, while AFP is elevated in HCC, it may also be increased in patients with active hepatitis or cirrhosis without malignancy. Novel biomarkers like des-gamma-carboxy prothrombin (DCP) and Glypican-3 have been investigated for better specificity in distinguishing HCC from cirrhosis (Marrero et al., 2009). Furthermore, integrating imaging with biomarker panels—such as the GALAD score, which combines gender, age, AFP-L3, AFP, and DCP—has shown improved diagnostic performance (Johnson et al., 2014). Nevertheless, the presence of fibrosis-related biomarkers such as TIMP-1 and PIIINP in both cirrhosis and HCC

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 3 May-June 2025, pp: 1610-1616 www.ijprajournal.com ISSN: 2456-4494

complicates the establishment of clear diagnostic boundaries. Thus, ongoing research is focused on identifying biomarker combinations and longitudinal monitoring approaches that can improve diagnostic accuracy in cirrhotic patients progressing to HCC.

II. CONCLUSION

Liver diseases are complex and progressive conditions that require timely diagnosis and effective monitoring to prevent irreversible damage and improve patient outcomes. Biomarkers play a vital role in understanding liver pathology, guiding therapeutic decisions, and evaluating disease progression. Among the various biomarkers studied, Tissue Inhibitor of Metalloproteinase-1 (TIMP-1) has emerged as a key indicator of liver fibrosis due to its involvement in extracellular matrix regulation and fibrogenesis. Its incorporation into non-invasive diagnostic panels such as the ELF score enhances the accuracy of fibrosis assessment without the need for liver biopsy. However, despite their clinical utility, the interpretation of biomarkers like TIMP-1 requires consideration of various confounding factors, including age, comorbidities, and assay variability. Advancements in molecular biology and the integration of multi-omics approaches hold promise for identifying more precise and personalized biomarker signatures. As research progresses, the combination of traditional and emerging biomarkers will likely transform liver disease diagnosis and management, making it more patient-centered, non-invasive, and effective.

REFERENCES

[1]. Bataller, R., & Brenner, D. A. (2005). Liver fibrosis. The Journal of Clinical Investigation, 115(2), 209–218. https://doi.org/10.1172/JCI24282

[2]. Rockey, D. C., Bell, P. D., & Hill, J. A. (2015). Fibrosis—A common pathway to organ injury and failure. The New England Journal of Medicine, 372(12), 1138–1149. https://doi.org/10.1056/NEJMra1300575

[3]. Friedman, S. L. (2008). Mechanisms of hepatic fibrogenesis. Gastroenterology, 134(6), 1655–1669. https://doi.org/10.1053/j.gastro.2008.03.003

[4]. European Association for the Study of the Liver (EASL). (2015). EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. Journal of Hepatology, 63(1), 237–264. https://doi.org/10.1016/j.jhep.2015.04.006

[5]. Gressner, A. M., &Weiskirchen, R. (2006). Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. Journal of Cellular and Molecular Medicine, 10(1), 76–99. https://doi.org/10.1111/j.1582-4934.2006.tb00292.x

[6]. Guéchot, J., et al. (2006). Diagnostic accuracy of hyaluronic acid and TIMP-1 serum levels in liver fibrosis. Clinical Biochemistry, 39(7), 708–713. https://doi.org/10.1016/j.clinbiochem.2006.03.005

[7]. Rosenberg, W. M. C., et al. (2004). Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology, 127(6), 1704–1713. https://doi.org/10.1053/j.gastro.2004.08.052

[8]. Lichtinghagen, R., & Bahr, M. J. (2004). Noninvasive markers of liver fibrosis: Clinical applications and limitations. Biological Chemistry, 385(11), 1073–1078. https://doi.org/10.1515/BC.2004.137

[9]. Bedossa, P., & Paradis, V. (2003). Liver extracellular matrix in health and disease. Journal of Pathology, 200(4), 504–515. https://doi.org/10.1002/path.1391

[10]. Castera, L., et al. (2005). Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology, 128(2), 343–350. https://doi.org/10.1053/j.gastro.2004.11.018

[11]. Valva, P., et al. (2015). MicroRNAs in chronic hepatitis C virus infection: Potential roles and clinical applications. World Journal of Gastroenterology, 21(30), 8333–8349. https://doi.org/10.3748/wjg.v21.i30.8333

[12]. Vlassara, H., & Uribarri, J. (2014). Advanced glycation end products (AGE) and diabetes: Cause, effect, or both? Current Diabetes Reports, 14(1), 453. https://doi.org/10.1007/s11892-013-0453-1

[13]. Munteanu, M., et al. (2016). Non-invasive assessment of liver fibrosis. Journal of

Hepatology, 65(5), 1006–1017. https://doi.org/10.1016/j.jhep.2016.06.013

[14]. Schuppan, D., & Afdhal, N. H. (2008). Liver cirrhosis. The Lancet, 371(9615), 838–851. https://doi.org/10.1016/S0140-6736(08)60383-9

[15]. Nielsen, M. J., et al. (2015). Plasma levels of YKL-40, a novel biomarker of fibrosis, in patients with liver disease. Scandinavian Journal of Clinical and Laboratory Investigation, 75(7), 594–602. https://doi.org/10.3109/00365513.2015.1057750

[16]. Wang, X., et al. (2021). TIMP-1 and liver fibrosis: Mechanisms and clinical applications. Frontiers in Pharmacology, 12, 676. https://doi.org/10.3389/fphar.2021.676

[17]. D'Ambrosio, R., et al. (2005). Performance of the enhanced liver fibrosis test in patients with chronic hepatitis C. Hepatology, 41(6), 1296–1305. https://doi.org/10.1002/hep.20794

[18]. Lee, T. H., et al. (2016). Usefulness of serum TIMP-1 as a predictor of liver fibrosis in NAFLD patients. Clinical Molecular Hepatology, 22(3), 392–401. https://doi.org/10.3350/cmh.2016.0009

[19]. Guha, I. N., et al. (2008). Noninvasive markers for assessing liver fibrosis. Liver International, 28(5), 667–679. https://doi.org/10.1111/j.1478-3231.2008.01742.x

[20]. Elpek, G. O. (2014). Cellular and molecular mechanisms in the pathogenesis of liver fibrosis: A review. World Journal of Gastroenterology, 20(10), 2856–2869. https://doi.org/10.3748/wjg.v20.i10.2856

[21]. Kim, B. K., et al. (2010). Non-invasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver International, 30(4), 569–575. https://doi.org/10.1111/j.1478-3231.2009.02184.x

[22]. Kisseleva, T., & Brenner, D. A. (2006). Hepatic stellate cells and the reversal of fibrosis. Journal of Gastroenterology and Hepatology, 21(S3), S84–S87. https://doi.org/10.1111/j.1440-1746.2006.04589.x

[23]. Marcellin, P., et al. (2009). Regression of liver fibrosis after treatment of chronic hepatitis B. Gastroenterology, 136(7), 2169–2179. https://doi.org/10.1053/j.gastro.2009.02.062

[24]. Shaheen, A. A., & Myers, R. P. (2007). Diagnostic accuracy of the APRI for the prediction of hepatitis C–related fibrosis: A systematic review. Hepatology, 46(3), 912–921. https://doi.org/10.1002/hep.21747

[25]. Zhang, D. Y., et al. (2020). Diagnostic performance of serum biomarkers for liver fibrosis in chronic hepatitis B patients. Journal of Clinical Gastroenterology, 54(7), 624–631. https://doi.org/10.1097/MCG.0000000000001307